BackNLS Pharmaceutics Ltd - Warrants (25/09/2025) Overview

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Total Assets

Latest total assets for NLSPW: $4.3M.

Get informed when a big investor buys or sells

+ Follow
Total Assets
$4.34M
263.45% YoYΔ $3.14M vs prior year quarter

Peer trimmed avg / median

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Total Assets History

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) vs. peers: Total Assets Comparison

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) Total Assets Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

NLS Pharmaceutics Ltd - Warrants (25/09/2025) (NLSPW) FAQ

As of the most recent data (June 2025), NLSPW shows a total assets of $4.3M. That compares with $1.2M in the prior-year period — up 263.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, NLSPW's total assets is now $4.3M (was $1.2M) — a 263.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether NLS Pharmaceutics Ltd - Warrants (25/09/2025) is outperforming or lagging.

Tracking NLSPW's total assets over time shows whether NLS Pharmaceutics Ltd - Warrants (25/09/2025) is scaling, shrinking, or reshaping that part of the business. The current reading is $4.3M That compares with $1.2M in the prior-year period — up 263.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this total assets page, Stockcircle has NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect total assets (currently $4.3M) with ownership activity and broader fundamentals.

NLS Pharmaceutics Ltd - Warrants (25/09/2025)'s total assets is $4.3M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.